Effect of Cervical Paraesophageal Lymph Node Metastasis Versus Supraclavicular Lymph Node Metastasis on the Overall Survival of Patients With Thoracic Esophageal Squamous Cell Carcinoma: An Observational Study

NCT ID: NCT06165094

Last Updated: 2023-12-11

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

122 participants

Study Classification

OBSERVATIONAL

Study Start Date

2009-01-01

Study Completion Date

2023-12-01

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The goal of this observational study is to learn about in health conditions of ESCC. The main question\[s\] it aims to answer are:

•Lymph node metastasis(LNM) in cervical paraesophageal or supraclavicular which influence OS more.

Participants will describe the main status quo after surgery

Researchers will compare Lymph node metastasis(LNM) in cervical paraesophageal and supraclavicular to see if dead.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Demographic and pathologic data, including gender, age, pathological T stage, pathological N stage, 8th tumor-node-metastasis (TNM) stage, tumor location, tumor grade, lymphovascular invasion, perineural invasion, LNM, cervical paraesophageal LNM, supraclavicular LNM, and radical resection, were collected from the Sichuan Cancer Hospital and Institute Esophageal Cancer Case Management (SCH-ECCM) database.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Esophageal Cancer

Keywords

Explore important study keywords that can help with search, categorization, and topic discovery.

oesophageal squamous cell carcinoma; cervical paraesophageal lymph node metastasis; supraclavicular lymph node metastasis; lymphadenectomy; esophagectomy

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

RETROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Diagnosed with supraclavicular LNM

There was no intervention(s) in any group

No interventions assigned to this group

Diagnosed with paraesophageal LNM

There was no intervention(s) in any group

No interventions assigned to this group

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* patients who had undergone esophagectomy and
* patients who exhibited LNM in the supraclavicular region.

Exclusion Criteria

* tumor location outside the thoracic region,
* pathological examination results confirming the presence of non-squamous cell carcinoma, - patients with both cervical paraesophageal LNM and supraclavicular LNM, or
* those with missing required data
Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Sichuan Cancer Hospital and Research Institute

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Yongtao Han

MD

Responsibility Role PRINCIPAL_INVESTIGATOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Sichaun cancer hospital

Chengdu, Sichuan, China

Site Status

Countries

Review the countries where the study has at least one active or historical site.

China

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

2023YFQ0056

Identifier Type: OTHER_GRANT

Identifier Source: secondary_id

SCCH-TS2206

Identifier Type: -

Identifier Source: org_study_id